BridgeBio Pharma secured $933.9 million through an Investment Agreement for Series A cumulative convertible participating preferred stock to support liquidity and its development programs. Purchasers, including Sixth Street and HCRx (a KKR affiliate), acquired 933,900 preferred shares at $1,000 each, featuring a 7.00% annual dividend and initial conversion price of $137.79 per share. Sixth Street also received an option to provide up to an additional $66.1 million on substantially identical terms, subject to Board approval. In a related move, BridgeBio executed a Registration Rights Agreement to file a resale shelf for common shares issuable upon conversion, enhancing investor liquidity.
Agreement 1: BridgeBio Pharma Raises $933.9 Million Via 7% Convertible Preferred From Sixth Street, HCRx
- Agreement type: Investment Agreement for Series A Cumulative Convertible Participating Preferred Stock
- Counterparty: Chinotto Investments and HCRx Investments HoldCo
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: At will
- Reason: Strengthen liquidity and fund growth and pipeline programs
Agreement 2: BridgeBio Pharma Agrees to Resale Shelf Registration for Preferred Conversion Shares
- Agreement type: Registration Rights Agreement for resale shelf
- Counterparty: Chinotto Investments and HCRx Investments HoldCo
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: At will
- Reason: Provide liquidity to investors
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.